OnCusp Therapeutics Welcomes Anthony Kim as New CFO to Drive Growth

OnCusp Therapeutics Welcomes Anthony Kim as New Chief Financial Officer

On May 14, 2026, OnCusp Therapeutics, Inc., a biopharmaceutical company focused on developing innovative oncology therapies, announced the strategic appointment of Anthony Kim as its new Chief Financial Officer (CFO). This move is aimed at bolstering the company's financial operations and preparing for future growth phases as OnCusp strives to translate advanced scientific innovations into meaningful patient outcomes.

Anthony Kim brings with him a robust portfolio of experience that spans over 25 years in finance, specifically in the biotechnology sector. His career includes leadership roles in both private and publicly traded life sciences firms, along with extensive experience in capital markets and investor relations. The depth of his knowledge in corporate strategy is expected to play a pivotal role in OnCusp's journey.

Bing Yuan, the Chief Executive Officer of OnCusp Therapeutics, emphasized Kim's suitability for the role, stating, "Anthony's extensive experience at the intersection of biotech and capital markets makes him an ideal fit for us as we advance our pipeline and prepare for future value inflection points. His track record of building strong investor relationships and executing complex financings will be instrumental to OnCusp's next phase of growth."

Most recently, Kim served as the Chief Financial Officer Consultant at Orum Therapeutics. In this role, he advised the company's CEO and Board on numerous critical matters, including U.S. capital markets strategy, valuation assessments, and managing investor engagement. His previous position as CFO at Marker Therapeutics, a publicly traded immuno-oncology company, saw him successfully navigate financial operations, corporate planning, and investor relations. Under his leadership, Marker Therapeutics secured over $130 million in equity financing while enhancing its capital position significantly.

Earlier in his career, Kim spent nearly two decades honing his investment banking skills at prestigious institutions like J.P. Morgan, Jefferies, Nomura, and Scotiabank. During this period, he executed equity, debt, and strategic transactions exceeding $30 billion, solidifying his reputation as a capable finance executive.

In his new role at OnCusp, Kim will spearhead the company’s capital markets strategy, financial planning, and investor relations initiatives. He will work closely with the executive team and Board of Directors to support ongoing growth and development efforts across the organization.

Kim holds an AB in Economics from the University of Chicago and earned his MBA from the UCLA Anderson School of Management. His educational background, combined with his extensive professional experience, positions him uniquely to contribute to OnCusp's mission of developing unique oncology therapies designed to transform patient care.

As OnCusp Therapeutics embarks on this new chapter with Anthony Kim at the helm of financial stewardship, stakeholders will be observing closely how his leadership influences the company's trajectory in the competitive biotech landscape.

For any inquiries regarding this announcement, you can reach out through OnCusp Therapeutics’ official channels.